%0 Journal Article
%T Review of Hyperuricemia as New Marker for Metabolic Syndrome
%A Laura Billiet
%A Sarah Doaty
%A James D. Katz
%A Manuel T. Velasquez
%J ISRN Rheumatology
%D 2014
%R 10.1155/2014/852954
%X Hyperuricemia has long been established as the major etiologic factor in gout. In recent years, a large body of evidence has accumulated that suggests that hyperuricemia may play a role in the development and pathogenesis of a number of metabolic, hemodynamic, and systemic pathologic diseases, including metabolic syndrome, hypertension, stroke, and atherosclerosis. A number of epidemiologic studies have linked hyperuricemia with each of these disorders. In some studies, therapies that lower uric acid may prevent or improve certain components of the metabolic syndrome. There is an association between uric acid and the development of systemic lupus erythematosus; the connection between other rheumatic diseases such as rheumatoid arthritis and osteoarthritis is less clear. The mechanism for the role of uric acid in disorders other than gout is not well established but recent investigations point towards systemic inflammation induced by urate, as the major pathophysiological event common to systemic diseases, including atherosclerosis. 1. Introduction More than 150 years ago, Garrod observed that uric acid is elevated in the blood of subjects with gout [1]. However, ultimate proof that uric acid is a causative factor in gout was not forthcoming for another 100 years when it was demonstrated that intra-articular injection of sodium urate produces acute arthritis [2]. Currently, it is well appreciated that chronic hyperuricemia enhances deposition of uric acid in tissues other than the joints, leading ultimately to tophi, nephropathy, and kidney stones. 2. Hyperuricemia Is Not Limited to Gout In recent years there has been a renewed interest in hyperuricemia and its association with a number of clinical disorders other than gout, including hypertension, atherosclerosis, cardiovascular disease, and chronic kidney disease. Indeed, hyperuricemia is commonly part of the cluster of metabolic and hemodynamic abnormalities including abdominal obesity, glucose intolerance, insulin resistance, dyslipidemia, and hypertension all often subsumed under the term ˇ°metabolic syndromeˇ± [3, 4]. Not only collectively, but also individually, hypertension, obesity, dyslipidemia, hyperglycemia, and insulin resistance are positively correlated with serum levels of uric acid [5¨C9]. 3. Hyperuricemia and Metabolic Syndrome and Its Components The association between uric acid and metabolic syndrome is robust throughout human development. Epidemiological studies have demonstrated a close relationship between serum uric acid (SUA) levels and the presence of metabolic syndrome (and
%U http://www.hindawi.com/journals/isrn.rheumatology/2014/852954/